PO.CTP01.01 · 进行中的临床试验

A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer

海报缩略图：A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer

编号 CT094 展板 25 时间 4/20 09:00–12:00 区域 Section 51 主讲 Sophia Frentzas, MD

分会场 Phase I Clinical Trials in Progress

查看完整资料下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Sophia Frentzas¹, Michelle Morris², Megan Barnet³, Niall Tebbutt⁴, Mark Wong⁵, Michael Michael⁶, Hyung-Don Kim⁷, Keun-Wook Lee⁸, Sun Young Rha⁹, Sang Cheul Oh¹⁰, I-Chen Wu¹¹, Li-Yuan Bai¹², Wen-Chi Chou¹³, Ming-Huang Chen¹⁴, Yen-Yang Chen¹⁵, Chia-Chi Lin¹⁶, Anthony Rodrigues³, Jason Ptacek¹⁷, Michael N. Alonso¹⁷, Tariq Arshad¹⁷, Jakob Dupont¹⁷, Kristi Balacy¹⁷, Sung Hee Lim¹⁸

¹Monash Medical Centre, Clayton, Australia,²Sunshine Coast University Hospital, Birtinya, Australia,³St Vincent Hospital Sydney (The Kinghorn Cancer Centre), Darlinghurst, Australia,⁴Austin Health, Heidelberg, Australia,⁵Westmead Hospital, Westmead, Australia,⁶Peter MacCallum Cancer Centre, Melbourne, Australia,⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of,⁸Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of,⁹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of,¹⁰Korea University Guro Hospital, Seoul, Korea, Republic of,¹¹Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan,¹²China Medical University Hospital, China Medical University, Taichung City, Taiwan,¹³Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan,¹⁴Taipei Veterans General Hospital, Taipei City, Taiwan,¹⁵Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan,¹⁶National Taiwan University Hospital, Taipei, Taiwan,¹⁷Bolt Biotherapeutics, Redwood City, CA,¹⁸Samsung Medical Center, Seoul, Korea, Republic of

摘要 Abstract

Background: Claudin 18.2 (CLDN18.2) is a transmembrane tight junction protein with expression restricted to the gastric mucosal epithelia where CLDN18.2 protects against paracellular acid leakage and associated gastritis. 1 CLDN18.2 overexpression has been observed in several tumor types, including gastric, esophageal, and pancreatic cancer. 2,3 Loss of cell polarity in these tumors results in CLDN18.2 localization to surfaces that are more readily accessible to biologics and effector cells. This expression pattern makes CLDN18.2 a compelling target for immune-stimulating antibody conjugates (ISACs) that combine the specificity of tumor-targeting antibodies with the potency and durability of immune activation. BDC-4182 is a next-generation ISAC consisting of a CLDN18.2-targeting antibody covalently attached to a novel toll-like receptor (TLR)7/8 agonist via a non-cleavable linker. In preclinical models, systemic delivery of ISACs has been shown to broadly activate the innate and adaptive immune system, leading to complete tumor regression. A BDC-4182 surrogate induced immunologic memory and epitope spreading as evidenced by rejection of tumor cells that no longer express the target antigen (CLDN18.2) following re-challenge. 4,5 Methods: This is a first-in-human Phase 1 dose escalation and Phase 2 expansion study of BDC-4182. Up to 122 patients with advanced gastric and gastroesophageal cancer will be enrolled. To optimize tolerability, BDC-4182 is administered via an intra-patient step-up dosing regimen wherein subjects receive lower initial priming doses prior to the target dose. Primary objectives are to define safety and tolerability and to determine the recommended phase 2 dose (RP2D) of BDC-4182 as a single agent. Secondary objectives will evaluate the preliminary anti-tumor activity of BDC-4182, analyze PK characteristics of BDC-4182, and evaluate the immunogenicity of BDC-4182 as a single agent. Exploratory analyses will also be conducted to explore potential biomarkers in blood and tumor tissue associated with exposure, efficacy, or safety of BDC-4182, and to define CLDN18 expression in tumor tissue. This study is being conducted in Australia, South Korea, and Taiwan. References: 1. Suzuki K, Sentani K, Tanaka H, et al. Cell Mol Gastroenterol Hepatol. 2019;8:119-142. 2. Hong JY, An JY, Lee J, et al. Transl Cancer Res. 2020;9:3367-3374. 3. Chen J, Xu Z, Hu C, et al. Front Oncol. 2023;13:1132319.4. Fu C, Luo A, Liu J, et al. J Immunother Cancer. 2024;12(Suppl 2):Abstract 1052. 5. Kim HK, Monnier J, Fu C, et al. J Immunother Cancer. 2023;11(Suppl 1):Abstract 1147-D.

利益披露 Disclosure

S. Frentzas, None.. M. Morris, None.. M. Barnet, None.. N. Tebbutt, None.. M. Wong, None.. M. Michael, None.. H. Kim, None. K. Lee, Bolt Biotherapeutics ). ALX Oncology ). Amgen ). Arcus ). Astellas Independent Contractor, ), Other, Honoraria / speaker fees. AstraZeneca ). BeOne ). Daiichi Sankyo Independent Contractor, ), Other, Honoraria / speaker fees. Exelixis ). AbbVie Independent Contractor. GSK ). Sanofi/Aventis ), Other, Honoraria / speaker fees. Immuneoncia Independent Contractor, ). Jazz ). Leap ). Medicenna ). MedPacto ). Merck KGaA Honoraria / speaker fees. Pfizer ). Roche ). S. Rha, None.. S. Oh, None.. I. Wu, None.. L. Bai, None.. W. Chou, None.. M. Chen, None.. Y. Chen, None.. C. Lin, None.. A. Rodrigues, None. J. Ptacek, Bolt Biotherapeutics Employment, Stock Option. M. N. Alonso, Bolt Biotherapeutics Employment, Stock Option. T. Arshad, Bolt Biotherapeutics Employment, Stock Option. J. Dupont, Bolt Biotherapeutics g., Board of Directors, non-salaried role). K. Balacy, Bolt Biotherapeutics Employment, Stock Option. S. Lim, None.

在会议检索中打开